Your browser doesn't support javascript.
loading
Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone.
Adeyanju, Oluwaseun A; Falodun, Timothy O; Fabunmi, Oyesanmi A; Olatunji, Lawrence A; Soladoye, Ayodele O.
Afiliación
  • Adeyanju OA; Cardiometabolic Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria; HOPE Cardiometabolic Research Team & Department of Physiology, University of Ilorin, Ilorin, Nigeria. Electronic address: adeyanjuoa@abuad.edu.ng.
  • Falodun TO; Cardiometabolic Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
  • Fabunmi OA; Department of Physiology, Ekiti State University, Ado-Ekiti, Nigeria.
  • Olatunji LA; HOPE Cardiometabolic Research Team & Department of Physiology, University of Ilorin, Ilorin, Nigeria.
  • Soladoye AO; Cardiometabolic Research Unit, Department of Physiology, College of Health and Medical Sciences, Bowen University, Iwo, Nigeria.
Chem Biol Interact ; 310: 108742, 2019 Sep 01.
Article en En | MEDLINE | ID: mdl-31295448

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome del Ovario Poliquístico / Espironolactona / Testosterona / Resistencia a la Insulina Límite: Animals Idioma: En Revista: Chem Biol Interact Año: 2019 Tipo del documento: Article Pais de publicación: Irlanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome del Ovario Poliquístico / Espironolactona / Testosterona / Resistencia a la Insulina Límite: Animals Idioma: En Revista: Chem Biol Interact Año: 2019 Tipo del documento: Article Pais de publicación: Irlanda